Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Short term Debt (2019 - 2025)

OptimizeRx's Short term Debt history spans 4 years, with the latest figure at $3.3 million for Q3 2025.

  • For Q3 2025, Short term Debt rose 65.0% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $3.3 million, up 65.0%, while the annual FY2024 figure was $2.0 million, 0.0% changed from the prior year.
  • Short term Debt for Q3 2025 was $3.3 million at OptimizeRx, roughly flat from $3.3 million in the prior quarter.
  • Across five years, Short term Debt topped out at $3.5 million in Q1 2024 and bottomed at $2.0 million in Q4 2023.
  • The 3-year median for Short term Debt is $3.3 million (2024), against an average of $2.8 million.
  • The largest YoY upside for Short term Debt was 65.0% in 2025 against a maximum downside of 5.71% in 2025.
  • A 3-year view of Short term Debt shows it stood at $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then surged by 65.0% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Short term Debt are $3.3 million (Q3 2025), $3.3 million (Q2 2025), and $3.3 million (Q1 2025).